STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (BSX) director receives $215,000 restricted stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Habiger David C reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director David C. Habiger received an annual equity award of 3,800 shares of common stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. According to the filing, the grant reflects a value of $215,000, based on the closing price of the common stock on the grant date. After this grant, Habiger directly holds 9,428 shares of Boston Scientific common stock.

Positive

  • None.

Negative

  • None.
Insider Habiger David C
Role null
Type Security Shares Price Value
Grant/Award Common Stock 3,800 $0.00 --
Holdings After Transaction: Common Stock — 9,428 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Restricted stock grant 3,800 shares Annual equity award to director on grant date
Award value $215,000 Value divided by closing price to determine shares
Shares owned after grant 9,428 shares Total direct holdings following the transaction
restricted stock financial
"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
annual equity award financial
"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Habiger David C
(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A(1)3,800A$0.00009,428D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
/s/ Susan Thompson, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Boston Scientific (BSX) director David Habiger report on this Form 4?

David C. Habiger reported receiving an equity award of 3,800 Boston Scientific common shares. The award is restricted stock granted as director compensation and vests in full at the next annual stockholder meeting, increasing his direct holdings to 9,428 shares.

Was the Boston Scientific (BSX) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant of shares, not a market trade. Habiger received 3,800 restricted shares as an annual equity award at no purchase price, so it is compensation-related rather than an open-market buy or sell transaction.

What is the value of the equity award reported by Boston Scientific (BSX)?

The equity award has a stated value of $215,000. This value is calculated by dividing $215,000 by the closing price of Boston Scientific’s common stock on the grant date to determine the 3,800 restricted shares granted to director David C. Habiger.

How many Boston Scientific (BSX) shares does David Habiger own after this filing?

After the reported grant, David C. Habiger directly owns 9,428 Boston Scientific common shares. This total reflects the addition of 3,800 restricted shares awarded as annual director compensation, which will vest at the company’s next annual stockholder meeting.

When do the restricted stock awards to the Boston Scientific (BSX) director vest?

The 3,800 restricted shares vest in full at the next annual meeting of stockholders. Until vesting, they are subject to restrictions, but they represent part of David C. Habiger’s director compensation and are included in his reported direct holdings.